{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T02:56:23Z","timestamp":1781146583098,"version":"3.54.1"},"reference-count":84,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To quantify the association between circulating fatty acid\u2013binding protein 4 (FABP4) levels and the risk of major adverse cardiovascular events (MACEs) and secondary cardiovascular outcomes in prospective cohort studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library from inception to 1 December 2025 for prospective cohort studies evaluating baseline FABP4 levels in relation to subsequent cardiovascular outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects models, and dose\u2013response analyses were performed. Thirty-five prospective cohort studies were included (PROSPERO: CRD420261291090). In the pooled analysis, participants in the highest FABP4 category, as defined within each study, had a 61.6% higher risk of MACE than those in the lowest category (HR = 1.616, 95% CI: 1.402\u20131.863; I2 = 35.0%). This association remained significant when FABP4 was analysed as a continuous variable (HR = 1.393, 95% CI: 1.181\u20131.643; I2 = 79.9%). Higher FABP4 levels were also associated with higher risks of secondary cardiovascular outcomes, including cardiovascular death, heart failure, and myocardial infarction. In linear dose\u2013response analyses, each 10\u2005ng\/mL higher baseline FABP4 level was associated with a 16.6% higher risk of MACE and a 13.1% higher risk of cardiovascular death, with no evidence of non-linearity. Sensitivity analyses yielded similar results, and no substantial publication bias was detected for the primary MACE analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Higher FABP4 levels were associated with higher risks of MACE and cardiovascular death, supporting its potential relevance as a prognostic marker warranting further evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwag276","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T08:36:47Z","timestamp":1779179807000},"source":"Crossref","is-referenced-by-count":0,"title":["Fatty acid\u2013binding protein 4 and major adverse cardiovascular events: a dose\u2013response meta-analysis of prospective cohort studies"],"prefix":"10.1093","author":[{"given":"Yanjie","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine , No. 157 Daming Road, Nanjing 210022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine , Chengdu 610072 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Lu","sequence":"additional","affiliation":[{"name":"No. 1 Clinical Medical College, Nanjing University of Chinese Medicine , Nanjing 210029 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine , Chengdu 610072 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyi","family":"He","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Guangzhou University of Chinese Medicine , Guangzhou 510006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine , No. 157 Daming Road, Nanjing 210022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Fu","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine , Chengdu 610072 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuran","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine , No. 157 Daming Road, Nanjing 210022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinwei","family":"Fu","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine , Chengdu 610072 ,","place":["China"]},{"name":"Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University , Hamilton , L8S 4L8","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine , No. 157 Daming Road, Nanjing 210022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine , No. 157 Daming Road, Nanjing 210022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinxiu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine , Chengdu 610072 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine , No. 157 Daming Road, Nanjing 210022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7986-2599","authenticated-orcid":false,"given":"Yan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine , No. 157 Daming Road, Nanjing 210022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"2026061021580668300_zwag276-B1","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.jacc.2025.08.015","article-title":"Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990\u20132023","volume":"86","author":"Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026061021580668300_zwag276-B2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/CIRCULATIONAHA.119.041022","article-title":"Impact of regulatory guidance on evaluating cardiovascular risk of new glucose-lowering therapies to treat type 2 diabetes Mellitus: lessons learned and future directions","volume":"141","author":"Sharma","year":"2020","journal-title":"Circulation"},{"key":"2026061021580668300_zwag276-B3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12933-025-02711-x","article-title":"Improved prediction and risk stratification of major adverse cardiovascular events using an explainable machine learning approach combining plasma biomarkers and traditional risk factors","volume":"24","author":"Zhang","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"2026061021580668300_zwag276-B4","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"2026061021580668300_zwag276-B5","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"2026061021580668300_zwag276-B6","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.jcmg.2025.04.008","article-title":"Association of pericoronary adipose attenuation with Major adverse cardiovascular events and high-risk plaque","volume":"18","author":"Tan","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026061021580668300_zwag276-B7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41574-019-0230-6","article-title":"The endocrine function of adipose tissues in health and cardiometabolic disease","volume":"15","author":"Scheja","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"2026061021580668300_zwag276-B8","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrendo.2015.122","article-title":"Metabolic functions of FABPs\u2013mechanisms and therapeutic implications","volume":"11","author":"Hotamisligil","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"2026061021580668300_zwag276-B9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12933-025-03034-7","article-title":"Proteomic signature of metabolic dysfunction-associated steatotic liver disease and risk of atherosclerotic cardiovascular disease","volume":"25","author":"Pan","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"2026061021580668300_zwag276-B10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/procel\/pwaf072","article-title":"Systematic analyses uncover plasma proteins linked to incident cardiovascular diseases","volume":"17","author":"Chen","year":"2026","journal-title":"Protein Cell"},{"key":"2026061021580668300_zwag276-B11","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jfma.2020.08.007","article-title":"Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions","volume":"120","author":"Tsai","year":"2021","journal-title":"J Formosan Med Assoc"},{"key":"2026061021580668300_zwag276-B12","doi-asserted-by":"crossref","first-page":"16501","DOI":"10.1038\/s41598-021-95534-1","article-title":"Association of free fatty acid binding protein with central aortic stiffness, myocardial dysfunction and preserved ejection fraction heart failure","volume":"11","author":"Yen","year":"2021","journal-title":"Sci Rep"},{"key":"2026061021580668300_zwag276-B13","doi-asserted-by":"crossref","first-page":"2262624","DOI":"10.1080\/0886022X.2023.2262624","article-title":"Elevated serum fatty acid-binding protein 4 level predicts all-cause and cardiovascular mortality in peritoneal dialysis patients: a five-year study","volume":"45","author":"Zhou","year":"2023","journal-title":"Ren Fail"},{"key":"2026061021580668300_zwag276-B14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/joim.13116","article-title":"Use of proteomics to identify biomarkers associated with chronic kidney disease and long-term outcomes in patients with myocardial infarction","volume":"288","author":"Edfors","year":"2020","journal-title":"J Intern Med"},{"key":"2026061021580668300_zwag276-B15","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2337\/dc17-0068","article-title":"Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: should unstable angina be included in the primary end point?","volume":"40","author":"Marx","year":"2017","journal-title":"Diabetes Care"},{"key":"2026061021580668300_zwag276-B16","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.jacc.2025.10.055","article-title":"Using artificial intelligence to adjudicate Major adverse cardiovascular events in clinical trials","volume":"87","author":"Marti-Castellote","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"2026061021580668300_zwag276-B17","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jacc.2025.07.056","article-title":"Impact of obicetrapib on major adverse cardiovascular events in high-risk patients: a pooled analysis","volume":"86","author":"Nicholls","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026061021580668300_zwag276-B18","doi-asserted-by":"crossref","DOI":"10.1177\/10760296251401588","article-title":"Genetic association of FABP4 with cardiovascular events: a Mendelian randomization study","volume":"31","author":"Zhang","year":"2025","journal-title":"Clin Appl Thromb Hemost"},{"key":"2026061021580668300_zwag276-B19","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13684","article-title":"Adipokines and stroke: a systematic review and meta-analysis of disease risk and patient outcomes","volume":"25","author":"Agbaedeng","year":"2024","journal-title":"Obes Rev"},{"key":"2026061021580668300_zwag276-B20","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/1092263","article-title":"Circulating FABP-4 levels in patients with atherosclerosis or coronary artery disease: a comprehensive systematic review and meta-analysis","volume":"2023","author":"Jalilian","year":"2023","journal-title":"Cardiovasc Ther"},{"key":"2026061021580668300_zwag276-B21","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical research ed)"},{"key":"2026061021580668300_zwag276-B22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002742","article-title":"COSMOS-E: guidance on conducting systematic reviews and meta-analyses of observational studies of etiology","volume":"16","author":"Dekkers","year":"2019","journal-title":"PLoS Med"},{"key":"2026061021580668300_zwag276-B23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.envint.2018.07.015","article-title":"Identifying the PECO: a framework for formulating good questions to explore the association of environmental and other exposures with health outcomes","volume":"121","author":"Morgan","year":"2018","journal-title":"Environ Int"},{"key":"2026061021580668300_zwag276-B24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"2026061021580668300_zwag276-B25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"key":"2026061021580668300_zwag276-B26","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"2026061021580668300_zwag276-B27","first-page":"557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical research ed)"},{"key":"2026061021580668300_zwag276-B28","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ (Clinical research ed)"},{"key":"2026061021580668300_zwag276-B29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"Higgins","year":"2009","journal-title":"J R Statist Soc Ser A, (Statistics in Society)"},{"key":"2026061021580668300_zwag276-B30","first-page":"629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical research ed)"},{"key":"2026061021580668300_zwag276-B31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/eb-2013-101699","article-title":"How to assess publication bias: funnel plot, trim-and-fill method and selection models","volume":"17","author":"Mavridis","year":"2014","journal-title":"Evid Based Ment Health"},{"key":"2026061021580668300_zwag276-B32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2026061021580668300_zwag276-B33","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/oxfordjournals.aje.a116237","article-title":"Methods for trend estimation from summarized dose-response data, with applications to meta-analysis","volume":"135","author":"Greenland","year":"1992","journal-title":"Am J Epidemiol"},{"key":"2026061021580668300_zwag276-B34","doi-asserted-by":"publisher","author":"Orsini","DOI":"10.1177\/1536867X0600600103"},{"key":"2026061021580668300_zwag276-B35","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1177\/0962280218773122","article-title":"One-stage dose-response meta-analysis for aggregated data","volume":"28","author":"Crippa","year":"2019","journal-title":"Stat Methods Med Res"},{"key":"2026061021580668300_zwag276-B36","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00001648-199507000-00005","article-title":"Dose-response and trend analysis in epidemiology: alternatives to categorical analysis","volume":"6","author":"Greenland","year":"1995","journal-title":"Epidemiology (Cambridge, Mass)"},{"key":"2026061021580668300_zwag276-B37","doi-asserted-by":"crossref","first-page":"7434","DOI":"10.1007\/s00415-024-12672-y","article-title":"Physical activity and risk of Parkinson's disease: an updated systematic review and meta-analysis","volume":"271","author":"Jiang","year":"2024","journal-title":"J Neurol"},{"key":"2026061021580668300_zwag276-B38","author":"Wells"},{"key":"2026061021580668300_zwag276-B39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2026061021580668300_zwag276-B40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"2026061021580668300_zwag276-B41","doi-asserted-by":"crossref","first-page":"e28785","DOI":"10.1371\/journal.pone.0028785","article-title":"Fatty acid binding protein 4 is associated with carotid atherosclerosis and outcome in patients with acute ischemic stroke","volume":"6","author":"Holm","year":"2011","journal-title":"PLoS One"},{"key":"2026061021580668300_zwag276-B42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027356","article-title":"Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease","volume":"6","author":"Furuhashi","year":"2011","journal-title":"PLoS One"},{"key":"2026061021580668300_zwag276-B43","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/eurheartj\/ehq387","article-title":"Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events","volume":"32","author":"Peeters","year":"2011","journal-title":"Eur Heart J"},{"key":"2026061021580668300_zwag276-B44","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1161\/ATVBAHA.112.248609","article-title":"Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study","volume":"32","author":"von Eynatten","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026061021580668300_zwag276-B45","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.004176","article-title":"Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: a 12-year prospective study","volume":"2","author":"Chow","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026061021580668300_zwag276-B46","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/eurjhf\/hfs196","article-title":"Fatty acid-binding protein 4 and incident heart failure: the Cardiovascular Health Study","volume":"15","author":"Djouss\u00e9","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026061021580668300_zwag276-B47","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1161\/ATVBAHA.116.308320","article-title":"Plasma levels of fatty acid-binding protein 4, retinol-binding protein 4, high-molecular-weight adiponectin, and cardiovascular mortality among men with type 2 diabetes: a 22-year prospective study","volume":"36","author":"Liu","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026061021580668300_zwag276-B48","first-page":"377","article-title":"Discovery of new biomarkers for atrial fibrillation using a custom-made proteomics chip","volume":"103","author":"Lind","year":"2017","journal-title":"Heart (British Cardiac Society)"},{"key":"2026061021580668300_zwag276-B49","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12872-017-0691-2","article-title":"Circulating adipocyte fatty acid-binding protein is a predictor of cardiovascular events in patients with stable angina undergoing percutaneous coronary intervention","volume":"17","author":"Takagi","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"2026061021580668300_zwag276-B50","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1161\/STROKEAHA.117.017128","article-title":"Circulating FABP4 (fatty acid-binding protein 4) is a novel prognostic biomarker in patients with acute ischemic stroke","volume":"48","author":"Tu","year":"2017","journal-title":"Stroke"},{"key":"2026061021580668300_zwag276-B51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clinbiochem.2017.12.010","article-title":"Association of vascular indices with novel circulating biomarkers as prognostic factors for cardiovascular complications in patients with type 2 diabetes mellitus","volume":"53","author":"Naka","year":"2018","journal-title":"Clin Biochem"},{"key":"2026061021580668300_zwag276-B52","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.7150\/ijms.25588","article-title":"High levels of serum adipocyte fatty acid-binding protein predict cardiovascular events in coronary artery disease patients","volume":"15","author":"Huang","year":"2018","journal-title":"Int J Med Sci"},{"key":"2026061021580668300_zwag276-B53","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1161\/ATVBAHA.118.311726","article-title":"Age-biomarkers-clinical risk factors for prediction of cardiovascular events in patients with coronary artery disease","volume":"38","author":"Wong","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026061021580668300_zwag276-B54","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1177\/0003319717728226","article-title":"FABP4 and cardiovascular events in peripheral arterial disease","volume":"69","author":"H\u00f6baus","year":"2018","journal-title":"Angiology"},{"key":"2026061021580668300_zwag276-B55","first-page":"5991","article-title":"Fatty acid-binding protein 4 and risk of type 2 diabetes, myocardial infarction, and stroke: a prospective cohort study","volume":"104","author":"Aleksandrova","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061021580668300_zwag276-B56","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.18632\/aging.101886","article-title":"Serum fatty acid binding protein 4 is positively associated with early stroke recurrence in nondiabetic ischemic stroke","volume":"11","author":"Li","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"2026061021580668300_zwag276-B57","doi-asserted-by":"crossref","first-page":"13097","DOI":"10.1038\/s41598-020-69473-2","article-title":"Using proximity extension proteomics assay to discover novel biomarkers associated with circulating leptin levels in patients with type 2 diabetes","volume":"10","author":"Vavruch","year":"2020","journal-title":"Sci Rep"},{"key":"2026061021580668300_zwag276-B58","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12933-020-01167-5","article-title":"Association between adipocyte fatty acid-binding protein with left ventricular remodelling and diastolic function in type 2 diabetes: a prospective echocardiography study","volume":"19","author":"Wu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2026061021580668300_zwag276-B59","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jchf.2019.11.005","article-title":"Distinct pathological pathways in patients with heart failure and diabetes","volume":"8","author":"Tromp","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026061021580668300_zwag276-B60","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1002\/ehf2.13036","article-title":"Proteomic exploration of common pathophysiological pathways in diabetes and cardiovascular disease","volume":"7","author":"Molvin","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026061021580668300_zwag276-B61","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/ehf2.13071","article-title":"Pathophysiological role of fatty acid-binding protein 4 in Asian patients with heart failure and preserved ejection fraction","volume":"7","author":"Harada","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026061021580668300_zwag276-B62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2020.06.013","article-title":"The association between plasma proteomics and incident cardiovascular disease identifies MMP-12 as a promising cardiovascular risk marker in patients with chronic kidney disease","volume":"307","author":"Feldreich","year":"2020","journal-title":"Atherosclerosis"},{"key":"2026061021580668300_zwag276-B63","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014070","article-title":"Fatty acid binding protein-4 and risk of cardiovascular disease: the cardiovascular health study","volume":"9","author":"Egbuche","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026061021580668300_zwag276-B64","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jacc.2019.12.069","article-title":"Multiple plasma biomarkers for risk stratification in patients with heart failure and preserved ejection fraction","volume":"75","author":"Chirinos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026061021580668300_zwag276-B65","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1038\/s41598-021-83494-5","article-title":"Elevated circulating FABP4 concentration predicts cardiovascular death in a general population: a 12-year prospective study","volume":"11","author":"Saito","year":"2021","journal-title":"Sci Rep"},{"key":"2026061021580668300_zwag276-B66","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/1747493020971166","article-title":"Time-dependent, dynamic prediction of fatty acid-binding protein 4, Galectin-3, and soluble ST2 measurement with poor outcome after acute stroke","volume":"16","author":"Hansen","year":"2021","journal-title":"Int J Stroke"},{"key":"2026061021580668300_zwag276-B67","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1002\/ehf2.13472","article-title":"Prospective association of serum adipocyte fatty acid-binding protein with heart failure hospitalization in diabetes","volume":"8","author":"Lee","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026061021580668300_zwag276-B68","doi-asserted-by":"crossref","first-page":"589206","DOI":"10.3389\/fimmu.2021.589206","article-title":"Adipocyte fatty acid-binding protein, cardiovascular diseases and mortality","volume":"12","author":"Lee","year":"2021","journal-title":"Front Immunol"},{"key":"2026061021580668300_zwag276-B69","doi-asserted-by":"crossref","first-page":"11107","DOI":"10.3390\/ijms231911107","article-title":"The role of fatty acid-binding protein 4 in the characterization of atrial fibrillation and the prediction of outcomes after catheter ablation","volume":"23","author":"L\u00f3pez-Canoa","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026061021580668300_zwag276-B70","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ehf2.14578","article-title":"Sex-specific cardiovascular protein levels and their link with clinical outcome in heart failure","volume":"11","author":"de Bakker","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026061021580668300_zwag276-B71","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2147\/JIR.S494049","article-title":"Elevated circulating adipocyte-fatty acid binding protein levels predict incident ischemic cardiovascular events in a longitudinal and prospective AMI aging study","volume":"18","author":"Zhao","year":"2025","journal-title":"J Inflamm Res"},{"key":"2026061021580668300_zwag276-B72","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ajcnut.2025.05.020","article-title":"Relationship of healthy lifestyle with healthy aging and the mediation by plasma proteins: a prospective cohort study","volume":"122","author":"Fang","year":"2025","journal-title":"Am J Clin Nutr"},{"key":"2026061021580668300_zwag276-B73","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1475-2840-11-72","article-title":"Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells","volume":"11","author":"Aragon\u00e8s","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"2026061021580668300_zwag276-B74","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1475-2840-12-105","article-title":"Association between serum adipocyte fatty-acid binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary artery disease","volume":"12","author":"Huang","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"2026061021580668300_zwag276-B75","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1186\/s12916-024-03791-4","article-title":"Single-cell analysis reveals the loss of FABP4-positive proliferating valvular endothelial cells relates to functional mitral regurgitation","volume":"22","author":"Wang","year":"2024","journal-title":"BMC Med"},{"key":"2026061021580668300_zwag276-B76","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd2589","article-title":"Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets","volume":"7","author":"Furuhashi","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"2026061021580668300_zwag276-B77","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.atherosclerosis.2005.10.041","article-title":"Lipid metabolism mediated by adipocyte lipid binding protein (ALBP\/aP2) gene expression in human THP-1 macrophages","volume":"188","author":"Fu","year":"2006","journal-title":"Atherosclerosis"},{"key":"2026061021580668300_zwag276-B78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-023-02096-9","article-title":"Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network","volume":"23","author":"Garc\u00eda-Vega","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026061021580668300_zwag276-B79","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5551\/jat.48710","article-title":"Fatty acid-binding protein 4 in cardiovascular and metabolic diseases","volume":"26","author":"Furuhashi","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"2026061021580668300_zwag276-B80","doi-asserted-by":"crossref","first-page":"R173","DOI":"10.1530\/JOE-17-0031","article-title":"Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease","volume":"233","author":"Rodr\u00edguez-Calvo","year":"2017","journal-title":"J Endocrinol"},{"key":"2026061021580668300_zwag276-B81","first-page":"23","article-title":"Fatty acid-binding protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases","volume":"8","author":"Furuhashi","year":"2014","journal-title":"Clin Med Insights Cardiol"},{"key":"2026061021580668300_zwag276-B82","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41374-021-00679-2","article-title":"FABP4 activates the JAK2\/STAT2 pathway via Rap1a in the homocysteine-induced macrophage inflammatory response in ApoE(-\/-) mice atherosclerosis","volume":"102","author":"Xu","year":"2022","journal-title":"Lab Invest"},{"key":"2026061021580668300_zwag276-B83","doi-asserted-by":"crossref","first-page":"9386","DOI":"10.3390\/ijms22179386","article-title":"A-FABP in metabolic diseases and the therapeutic implications: an update","volume":"22","author":"Li","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026061021580668300_zwag276-B84","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review","volume":"21","author":"Bosco","year":"2021","journal-title":"BMC Med Res Methodol"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag276\/68332942\/zwag276.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag276\/68332942\/zwag276.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:58:21Z","timestamp":1781143101000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag276\/8687212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":84,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag276","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"article-number":"zwag276"}}